Logo

American Heart Association

  180
  0


Final ID:

Discussant: REALIZE-K

  • Zannad, Faiez  ( CVCT and Universite de Lorraine , Paris , France )
  • Allen, Larry  ( UNIVERSITY COLORADO DENVER , Aurora , Colorado , United States )
  • Author Disclosures:
    Faiez ZANNAD: DO have relevant financial relationships ; Advisor:NovoNordisk:Past (completed) ; Advisor:Northsea:Expected (by end of conference) ; Advisor:Merck:Active (exists now) ; Advisor:CEVA:Past (completed) ; Advisor:Cellprothera:Active (exists now) ; Advisor:Cereno:Active (exists now) ; Ownership Interest:CVCT:Active (exists now) ; Advisor:Cardior:Past (completed) ; Advisor:CVRx:Active (exists now) ; Advisor:BMS:Past (completed) ; Advisor:Boehringer:Active (exists now) ; Advisor:Biopeutics:Active (exists now) ; Consultant:Owkin:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Advisor:Applied Therapeutics:Past (completed) | Larry Allen: DO have relevant financial relationships ; Consultant:ACI Clinical:Active (exists now) ; Researcher:PCORI:Active (exists now) ; Researcher:NIH:Active (exists now) ; Consultant:UpToDate:Active (exists now) ; Consultant:Quidel:Active (exists now) ; Consultant:Novartis:Past (completed) ; Consultant:Cytokinetics:Past (completed) ; Consultant:Boston Scientific:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Building on the 4 Pillars: Novel Trials of Medical Therapy for Heart Failure

Monday, 11/18/2024 , 08:00AM - 09:15AM

Late-Breaking Science

More abstracts on this topic:
Discussant: RSQ-777-02

Testani Jeffrey, Ommen Steve, Patel Ravi

Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide

Kolski Brian, Bensimhon Daniel, Adler Eric, Kapur Navin, Lala Anuradha, Macaluso Gregory, Hajduczok Alexander, Neutel Joel

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available